Logo image of ALEC

ALECTOR INC (ALEC) Stock Fundamental Analysis

NASDAQ:ALEC - Nasdaq - US0144421072 - Common Stock - Currency: USD

1.87  +0.01 (+0.54%)

After market: 1.87 0 (0%)

Fundamental Rating

3

Taking everything into account, ALEC scores 3 out of 10 in our fundamental rating. ALEC was compared to 571 industry peers in the Biotechnology industry. The financial health of ALEC is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ALEC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALEC had negative earnings in the past year.
In the past year ALEC has reported a negative cash flow from operations.
ALEC had negative earnings in each of the past 5 years.
ALEC had negative operating cash flow in 4 of the past 5 years.
ALEC Yearly Net Income VS EBIT VS OCF VS FCFALEC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

1.2 Ratios

ALEC has a Return On Assets of -30.70%. This is in the better half of the industry: ALEC outperforms 66.79% of its industry peers.
ALEC has a worse Return On Equity (-133.19%) than 62.52% of its industry peers.
Industry RankSector Rank
ROA -30.7%
ROE -133.19%
ROIC N/A
ROA(3y)-14.12%
ROA(5y)-21.26%
ROE(3y)-57.15%
ROE(5y)-59.33%
ROIC(3y)N/A
ROIC(5y)N/A
ALEC Yearly ROA, ROE, ROICALEC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

ALEC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALEC Yearly Profit, Operating, Gross MarginsALEC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

More info and screens

6

2. Health

2.1 Basic Checks

ALEC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALEC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ALEC has been increased compared to 5 years ago.
ALEC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALEC Yearly Shares OutstandingALEC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
ALEC Yearly Total Debt VS Total AssetsALEC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

ALEC has an Altman-Z score of -2.26. This is a bad value and indicates that ALEC is not financially healthy and even has some risk of bankruptcy.
ALEC has a Altman-Z score (-2.26) which is comparable to the rest of the industry.
There is no outstanding debt for ALEC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.26
ROIC/WACCN/A
WACC9.44%
ALEC Yearly LT Debt VS Equity VS FCFALEC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 3.29 indicates that ALEC has no problem at all paying its short term obligations.
ALEC has a worse Current ratio (3.29) than 61.10% of its industry peers.
ALEC has a Quick Ratio of 3.29. This indicates that ALEC is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ALEC (3.29) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.29
Quick Ratio 3.29
ALEC Yearly Current Assets VS Current LiabilitesALEC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for ALEC have decreased by -0.59% in the last year.
The Revenue for ALEC has decreased by -36.06% in the past year. This is quite bad
ALEC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 28.50% yearly.
EPS 1Y (TTM)-0.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.87%
Revenue 1Y (TTM)-36.06%
Revenue growth 3Y66.31%
Revenue growth 5Y28.5%
Sales Q2Q%68.43%

3.2 Future

ALEC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.68% yearly.
Based on estimates for the next years, ALEC will show a small growth in Revenue. The Revenue will grow by 6.08% on average per year.
EPS Next Y-22.77%
EPS Next 2Y-8.94%
EPS Next 3Y3.84%
EPS Next 5Y10.68%
Revenue Next Year-31.32%
Revenue Next 2Y-17.08%
Revenue Next 3Y6.04%
Revenue Next 5Y6.08%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ALEC Yearly Revenue VS EstimatesALEC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
ALEC Yearly EPS VS EstimatesALEC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALEC. In the last year negative earnings were reported.
Also next year ALEC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALEC Price Earnings VS Forward Price EarningsALEC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALEC Per share dataALEC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.94%
EPS Next 3Y3.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALEC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALECTOR INC

NASDAQ:ALEC (2/21/2025, 8:00:49 PM)

After market: 1.87 0 (0%)

1.87

+0.01 (+0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners87.59%
Inst Owner Change-98.91%
Ins Owners7.25%
Ins Owner Change13.5%
Market Cap183.13M
Analysts77.33
Price Target4.93 (163.64%)
Short Float %6.43%
Short Ratio5.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.36%
Min EPS beat(2)21%
Max EPS beat(2)21.73%
EPS beat(4)4
Avg EPS beat(4)26.76%
Min EPS beat(4)21%
Max EPS beat(4)37.69%
EPS beat(8)7
Avg EPS beat(8)28.27%
EPS beat(12)8
Avg EPS beat(12)-9.58%
EPS beat(16)11
Avg EPS beat(16)-8.54%
Revenue beat(2)1
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-4.18%
Max Revenue beat(2)2.7%
Revenue beat(4)3
Avg Revenue beat(4)14.59%
Min Revenue beat(4)-4.18%
Max Revenue beat(4)54.54%
Revenue beat(8)5
Avg Revenue beat(8)137.07%
Revenue beat(12)6
Avg Revenue beat(12)88.4%
Revenue beat(16)6
Avg Revenue beat(16)58.45%
PT rev (1m)-17.48%
PT rev (3m)-64.85%
EPS NQ rev (1m)-4.58%
EPS NQ rev (3m)-3.73%
EPS NY rev (1m)-1.94%
EPS NY rev (3m)0.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.98
P/FCF N/A
P/OCF N/A
P/B 1.54
P/tB 1.54
EV/EBITDA N/A
EPS(TTM)-1.7
EYN/A
EPS(NY)-1.84
Fwd EYN/A
FCF(TTM)-2.27
FCFYN/A
OCF(TTM)-2.26
OCFYN/A
SpS0.63
BVpS1.21
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.7%
ROE -133.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.12%
ROA(5y)-21.26%
ROE(3y)-57.15%
ROE(5y)-59.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.38%
Cap/Sales 2.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.29
Quick Ratio 3.29
Altman-Z -2.26
F-Score1
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)54.77%
Cap/Depr(5y)130.34%
Cap/Sales(3y)2.36%
Cap/Sales(5y)20.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.87%
EPS Next Y-22.77%
EPS Next 2Y-8.94%
EPS Next 3Y3.84%
EPS Next 5Y10.68%
Revenue 1Y (TTM)-36.06%
Revenue growth 3Y66.31%
Revenue growth 5Y28.5%
Sales Q2Q%68.43%
Revenue Next Year-31.32%
Revenue Next 2Y-17.08%
Revenue Next 3Y6.04%
Revenue Next 5Y6.08%
EBIT growth 1Y-14.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.21%
EBIT Next 3Y3.25%
EBIT Next 5Y6.6%
FCF growth 1Y-807.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-972.52%
OCF growth 3YN/A
OCF growth 5YN/A